GlobalData’s report assesses the drugs in the Glucokinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Worldwide, at least 50 million people are believed to be living with a form of dementia. Alzheimer's disease is the most ...

Vidac Pharma’s two product candidates - VDA-1275 as well as the more advanced VDA-1102 - disrupt the interaction between hexokinase 2 (HK2) and the voltage-dependent anion channels (VDACs) in ...

Recent advances in neurobiology and PET have helped redefine Alzheimer's disease (AD) as a dynamic pathophysiological process, clinically characterized by preclinical, mild cognitive impairment ...

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class ...